Novo Nordisk: joins forces with Gilead on NASH disease

(CercleFinance.com) - Denmark's Novo Nordisk and US biotech firm Gilead Sciences are teaming up to initiate a clinical collaboration in non-alcoholic steatohepatitis (NASH), or fatty liver disease, the drugmakers said on Friday.


The companies intend to collaborate on a clinical trial that will be a proof-of-concept study combining compounds from their respective pipelines.

NASH is a chronic and progressive liver disease that is characterised by fat accumulation and inflammation in the liver. If left untreated, the disease can lead to serious consequences, including liver cancer and the need for liver transplantation.

Copyright (c) 2019 CercleFinance.com. All rights reserved.